WEE1 and cancer: The goals are to generate patient-derived organoids (PDOs), xenografts (PDXs), and PDX-derived organoids (PDXOs), evaluate the therapeutic potential of the WEE1 inhibitor AZD1775, and compare their responses to 18 anti-cancer drugs in PDOs and PDXOs.